Comparative analysis of the outcomes of COVID-19 between patients infected with SARS-CoV-2 Omicron and Delta variants: a retrospective cohort study

BackgroundThe SARS-CoV-2 Omicron variant has replaced the previously dominant Delta variant because of high transmissibility. It is responsible for the current increase in the COVID-19 infectivity rate worldwide. However, studies on the impact of the Omicron variant on the severity of COVID-19 are still limited in developing countries. Here, we compared the outcomes of patients infected with SARS-CoV-2 Omicron and Delta variants and associated with prognostic factors, including age, sex, comorbidities, and smoking. MethodsWe involved 352 patients, 139 with the Omicron variant and 213 with the Delta variant. The whole-genome sequences of SARS-CoV-2 were conducted using the Illumina MiSeq next-generation sequencer. ResultsCt value and mean age of COVID-19 patients were not significantly different between both groups (Delta: 20.35 {+/-} 4.07 vs. Omicron: 20.62 {+/-} 3.75; p=0.540; and Delta: 36.52 {+/-} 21.24 vs. Omicron: 39.10 {+/-} 21.24; p=0.266, respectively). Patients infected with Omicron and Delta variants showed similar hospitalization (p=0.433) and mortality rates (p=0.565). Multivariate analysis showed that older age ([≥]65 years) had higher risk for hospitalization (OR=3.67 [95% CI=1.22-10.94]; p=0.019) and fatalities (OR=3.93 [95% CI=1.35-11.42]; p=0.012). In addition, patients with cardiovascular disease had higher risk for hospitalization (OR=5.27 [95% CI=1.07-25.97]; p=0.041), whereas patients with diabetes revealed higher risk for fatalities (OR=9.39 [95% CI=3.30-26.72]; p=<0.001). ConclusionsOur study shows that patients infected with Omicron and Delta variants reveal similar clinical outcomes, including hospitalization and mortality. In addition, our findings further confirm that older age, cardiovascular disease, and diabetes are strong prognostic factors for the outcomes of COVID-19 patients.

Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients?

BackgroundSARS-CoV-2 Delta variant (B.1.617.2) has been responsible for the current increase in COVID-19 infectivity rate worldwide. We compared the impact of the Delta variant and non-Delta variant on the COVID-19 outcomes in patients from Yogyakarta and Central Java provinces, Indonesia. MethodsWe ascertained 161 patients, 69 with the Delta variant and 92 with the non-Delta variant. The Illumina MiSeq next-generation sequencer was used to perform the whole genome sequences of SARS-CoV-2. ResultsThe mean age of patients with Delta and the non-Delta variant was 27.3 {+/-} 20.0 and 43.0 {+/-} 20.9 (p=3x10-6). The patients with Delta variant consisted of 23 males and 46 females, while the patients with the non-Delta variant involved 56 males and 36 females (p=0.001). The Ct value of the Delta variant (18.4 {+/-} 2.9) was significantly lower than the non-Delta variant (19.5 {+/-} 3.8) (p=0.043). There was no significant difference in the hospitalization and mortality of patients with Delta and non-Delta variants (p=0.80 and 0.29, respectively). None of the prognostic factors was associated with the hospitalization, except diabetes with an OR of 3.6 (95% CI=1.02-12.5; p=0.036). Moreover, the patients with the following factors have been associated with higher mortality rate than patients without the factors: age [≥]65 years, obesity, diabetes, hypertension, and cardiovascular disease with the OR of 11 (95% CI=3.4-36; p=8x10-5), 27 (95% CI=6.1-118; p=1x10-5), 15.6 (95% CI=5.3-46; p=6x10-7), 12 (95% CI=4-35.3; p=1.2x10-5), and 6.8 (95% CI=2.1-22.1; p=0.003), respectively. Multivariate analysis showed that age [≥]65 years, obesity, diabetes, and hypertension were the strong prognostic factors for the mortality of COVID-19 patients with the OR of 3.6 (95% CI=0.58-21.9; p=0.028), 16.6 (95% CI=2.5-107.1; p=0.003), 5.5 (95% CI=1.3-23.7; p=0.021), and 5.8 (95% CI=1.02-32.8; p=0.047), respectively. ConclusionsWe show that the patients infected by the SARS-CoV-2 Delta variant have a lower Ct value than the patients infected by the non-Delta variant, implying that the Delta variant has a higher viral load, which might cause a more transmissible virus among humans. However, the Delta variant does not affect the COVID-19 outcomes in our patients. Our study also confirms the older age and comorbidity increase the mortality rate of COVID-19 patients.

In Vitro Antifungal Activity of (1)-N-2-Methoxybenzyl-1,10-phenanthrolinium Bromide against Candida albicans and Its Effects on Membrane Integrity

Metal-based drugs, such as 1,10-phenanthroline, have demonstrated anticancer, antifungal and antiplasmodium activities. One of the 1,10-phenanthroline derivatives compounds (1)-N-2-methoxybenzyl-1,10-phenanthrolinium bromide (FEN), which has been demonstrated an inhibitory effect on the growth of Candida spp. This study aimed to explore the in vitro antifungal activity of FEN and its effect on the membrane integrity of Candida albicans. The minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) of FEN against planktonic C. albicans cells were determined using the broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines. Cell membrane integrity was determined with the propidium iodide assay using a flow cytometer and were visualized using scanning electron microscopy (SEM). Planktonic cells growth of C. albicans were inhibited by FEN, with an MIC of 0.39–1.56 µg/mL and a MFC that ranged from 3.125 to 100 µg/mL. When C. albicans was exposed to FEN, the uptake of propidium iodide was increased, which indicated that membrane disruption is the probable mode of action of this compound. There was cells surface changes of C. albicans when observed under SEM.

Preliminary study of biofilm formation properties and antibiotic susceptibility pattern of MRSA and MSSA isolates obtained in Yogyakarta, Indonesia

Aims: Nowadays, Staphylococcus aureus, especially methicillin resistant Staphylococcus aureus (MRSA), emerged as a major pathogenic agent of nosocomial infection and sepsis worldwide. Infections caused by these bacteria are often difficult to treat because of the development of antibiotic resistance. Biofilm formation is an important factor in the pathogenicity of staphylococcal infections and one of the reason of antibiotic treatment failure. In this study, the relationship between biofilm formation properties, the presence of mecA, icaA/D genes and antimicrobial resistance pattern were investigated in 10 methicillin sensitive Staphylococcus aureus (MSSA) and 10 MRSA clinical isolates. Methodology and results: Staphylococcal strains were identified by conventional microbiological methods, while determination of methicillin susceptibility was distinguished by the presence of mecA gene. To investigate biofilm production, congo red agar and microtiter plate test were performed. PCR was done to detect the presence of icaA/D genes, which responsible for biofilm production. Antibiotic sensitivity was carried out by agar diffusion method. The majority of MRSA isolates (90%) were not able to form biofilm, only one isolate (10%) showed capability of weak biofilm producer. Meanwhile, fully established biofilms were formed by all of MSSA isolates (100%). In addition, all MRSA and almost MSSA isolates (90%) harboured both icaA/D genes in their chromosomes. Antibiotic resistance profile of MRSA was more dominant than MSSA isolates. Conclusion, significance, and impact of study: Biofilm production of staphylococci showed difference regulation with regard to methicillin susceptibility. Antibiotic resistance profile was more dominant in MRSA, however biofilm production was found mostly in MSSA isolates.